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sociated with leukemias (Rabbits, 1994). These includeKaren Rockwell,* Yuko Fujiwara,*‡ Frederick W. Alt,†‡
the basic–helix-loop-helix (bHLH) SCL/tal-1 (hereafterand Stuart H. Orkin*‡
designated SCL; Begley et al., 1989b; Finger et al, 1989;*Division of Hematology and Oncology
Chen et al, 1990), runt-related AML-1 (Erickson et al.,Children’s Hospital and Dana Farber Cancer Institute
1992; Miyoshi et al., 1991; Nucifora et al., 1993; GolubHarvard Medical School
et al., 1995; Romana et al., 1995), LIM Rbtn2 (LMO2;Boston, Massachusetts 02115
Boehm et al., 1988), and trithorax-related ALL-1 (Gu et†Department of Genetics
al., 1992; Rowley, 1993; Tkachuk et al., 1992) proteins.Harvard Medical School and Center for Blood Research
Deregulated expression of SCL and Rbtn2 and expres-Boston, Massachusetts 02115
sion of chimeric proteins containing portions of AML-1‡Howard Hughes Medical Institute
and ALL-1 are two pathways leading to leukemia. AChildren’s Hospital
requirement for each in aspects of hematopoiesis hasBoston, Massachusetts 02115
been established. SCL or Rbtn2 loss ablates embryonic
red cell production, leading to lethality prior to the ap-
pearance of other lineages (Shivdasani et al., 1995; War-Summary
ren et al., 1994). Absence of AML-1 prevents fetal liver,
but not yolk sac, hematopoiesis (Okuda et al., 1996),The T cell leukemia oncoprotein SCL/tal-1, a basic–
whereas ALL-1 haploinsufficiency has more subtle ef-helix-loop-helix transcription factor, is required for
fects (Yu et al., 1995).production of embryonic red blood cells in the mouse
SCL has emerged as a candidate regulator for earlyyolk sac. To define roles in other lineages, we studied
hematopoietic development. Following its discoverythe hematopoietic potential of homozygous mutant
through translocation into the T cell receptor d (TCRd)SCL/tal-1 2/2 embryonic stem cells upon in vitro dif-
locus in patients with acute lymphoblastic leukemiaferentiation and in vivo in chimeric mice. Here we show
(Begley et al., 1989b; Chen et al., 1990; Finger et al.,that in the absence of SCL/tal-1, hematopoiesis, in-
1989), SCL became recognized as a member of thecluding the generation of red cells, myeloid cells,
bHLH family of factors, several of which control develop-megakaryocytes, mast cells, and both T and B
ment in other lineages or organisms (Guillemot et al.,lymphoid cells, is undetectable. These findings sug-
1993; Lee et al., 1995; Murre et al., 1989; Olson andgest that SCL/tal-1 functions very early in hematopoi-
Klein, 1994; Rudnicki et al., 1993). For example, achaete-etic development, either in specification of ventral
scute controls fate decisions in the Drosophila nervous
mesoderm to a blood cell fate, or in formation or main-
system (Villares and Cabrera, 1987), whereas its mouse
tenance of immature progenitors.
homolog plays a more limited developmental role (Guil-
lemot et al., 1993). Of the myogeneic bHLH proteins,
Introduction myoD and myf5 participate in commitment, while myo-
genin and MRF4 act later in differentiation (Olson and
Blood cell production entails the generation of multiple Klein, 1994; Rudnicki et al., 1993).
distinct lineages (red cells, neutrophils, monocyte/mac- An early role for SCL in hematopoiesis is also sug-
rophages, platelets, mast cells, B and T lymphoid cells) gested by the immature phenotype of leukemic cells
from rare hematopoietic stem cells residing in the adult seen in humans with deregulated SCL expression (Beg-
bone marrow (Orkin, 1995). During vertebrate embryo- ley et al., 1989a). During normal embryogenesis in the
genesis, hematopoiesis occurs in successive waves. In mouse, SCL expression precedes or parallels the sites
mammals, embryonic red cells are produced in the yolk of hematopoiesis. Expression is detected in embryonic
sac blood islands. Cells of other lineages first appear and extraembryonic mesoderm at embryonic day 7.5
in the fetal liver at midgestation along with definitive (E7.5), in blood islands of the yolk sac by E8.5, and
(adult) red cells. Hematopoietic cells arise from ventral thereafter in adult hematopoietic tissues (Kallianpur et
mesoderm. al., 1994). Expression is restricted to multipotential my-
A central problem is the identification of genes that eloid and erythroid precursor cells, megakaryocytes,
participate in the developmental decisions leading to and mast cells (Green et al., 1991; Kallianpur et al., 1994;
formation of the hematopoietic system. Inactivation of a Mouthon et al., 1993; Visvader et al., 1991). SCL mRNA
gene of this class would ablate cells of all hematopoietic accumulates during differentiation of erythroleukemia
lineagesyet spare other developmental processes (such cells, consistent with a role in cellular maturation (Vis-
as vasculogenesis). Of the transcriptional regulators vader et al., 1991), as also suggested by dominant-nega-
studied in sufficient depth to assess their roles in hema- tive and antisense inhibition of SCL function (Aplan et
topoiesis, GATA-1 (Pevny et al., 1991), GATA-2 (Tsai et al., 1990). Expression of the SCL gene is not normally
al., 1994), Pu.1 (Scott et al., 1994), c-myb (Mucenski et detected in human lymphoid cell lines, suggesting that
al., 1991), Ikaros (Georgopoulos et al., 1994), ALL-1 (Yu its activation in T cells contributes to leukemogenesis
et al., 1995), and AML-1 (Okuda et al., 1996), none are (Visvader et al., 1991). In nonhematopoietic tissues, SCL
required in this global fashion. is expressed in progenitors of endothelial lineages in
blood islands, as well as in endothelial cells of otherSeveral nuclear factors important in hematopoiesis
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meration of precursors for individual (and mixed) non-
lymphoid lineages (Keller et al., 1993; Wiles and Keller,
1991). The appearance of hematopoietic precursors in
this system parallels that in the developing embryo (Kel-
ler et al.,1993). ES cells werepermitted to form embryoid
bodies (EBs) in semisolid methylcellulose media. At var-
ying days thereafter, EBs were disaggregated and cells
were replated in the presence of hematopoietic growth
factors favoring specific lineages. Primitive erythroid
(EryP), definitive (or adult) erythroid (EryD), and mega-
karyocyte precursor–derived colonies were generated
by growth in erythropoietin (Epo), erythropoietin plus kit-
ligand (Epo–KL), and thrombopoietin (Tpo), respectively.
Macrophage colonies were scored following growth in
Figure 1. Isolation of SCL 2/2 ES Cells G-CSF, GM-CSF, interleukin (IL)-3, and IL-11 and mixed
Genomic DNAs isolated from SCL 1/2 or SCL 2/2 (clone 1) ES colonies in a combination of all factors.
cells were digested with BamHI and probed as previously described
Both SCL 1/2 and 2/2 ES cells gave rise to EBs,(Shivdasani et al., 1995). wt, wild-type SCL allele; m, mutant allele.
but only SCL 1/2 EBs were surrounded by a halo of
macrophage-like cells (Figure 2A). On replating, SCL
organs (Hwang et al., 1993; Kallianpur et al., 1994). Fi-
1/2 EBs gave rise to colonies of all types (Figure 2A,
nally, SCL is expressed in several areas of the devel-
left column; Figure 2B). In contrast, no hematopoietic
oping brain (Green et al., 1992).
colonies were observed from SCL EBs derived from all
To define the in vivo role of SCL, we previously gener-
three homozygous mutant ES clones tested (Figure 2).
ated SCL 2/2 embryos by gene targeting of embryonic
These findings indicate that myeloerythroid hematopoi-
stem (ES) cells (Shivdasani et al., 1995). Remarkably,
esis, including formation or proliferation of precursors
these embryos contain no embryonic red cells and die
for erythroid, myeloid, and megakaryocytic cells, is un-between E9–10.5 due to anemia (Robb et al., 1995a;
detectable from SCL 2/2 ES cells.Shivdasani et al.,1995). Insights into roles in other hema-
topoietic lineages were limited by early embryonic le-
thality. No myeloid precursors were detected in E8.0–9.5
yolk sacs, reflecting either a primary effect of SCL loss Expression of Introduced SCL cDNA Rescues
or a consequence of profound anemia on precursor via- In Vitro Myeloerythroid Hematopoiesis
bility.
To exclude the possibility that this phenotype resulted
Our present work addresses the broader role of SCL
from altered expression of a gene neighboring the dis-
in hematopoiesis through study of the developmental
rupted SCL locus (Olson et al., 1996) or an inadvertent
potential of SCL 2/2 ES cells by two complementary
mutation in the ES cells, we undertook rescue of thestrategies. First, we evaluated the capacity of SCL 2/2
developmental defect by expression of wild-type SCLES cells to generate hematopoietic precursors upon in
cDNA introduced in a murine stem cell virus (MSCV)vitro differentiation (Keller et al., 1993; Wiles and Keller,
retroviral vector (Hawley et al., 1994). Small pools of1991). Second, we assessed hematopoiesis from SCL
MSCV–SCL cDNA–infected SCL 2/2 ES cells were iso-2/2 cells in vivo in chimeric mice. To validate our find-
lated and screened for expression of the SCL transcriptings, we also showed phenotypic rescue by expression
by reverse transcription–polymerase chain reactionof retrovirally transferred SCL cDNA. We demonstrate
(RT–PCR; data not shown). An expressing pool (SCLan absolute requirement for SCL in the generation of all
2/2R) was retained and tested for its in vitro hematopoi-hematopoietic lineages, a finding most compatible with
etic potential.a pivotal role in the earliest stages of hematopoiesis.
Appearance of macrophage-like cells surrounding
SCL 2/2R EBs initially suggested rescue of hematopoi-Results
esis (Figure 2A, top right). Upon replating of SCL 2/2R
EBs, hematopoietic colonies of all types were observedGeneration of SCL 2/2 ES Cells
(Figure 2A) at frequencies approximating those of 1/2SCL 2/2 ES cells were selected by exposure of SCL
cells (Figure 2B). To evaluate the level of expression of1/2 cells (Shivdasani et al., 1995) to an increased con-
the transgene in the SCL 2/2R ES cells and their prog-centration of G418 (Mortensen et al., 1992). Southern
eny, we performed semiquantitative RT–PCR analysesblot analysis identified homozygous mutant ES cells
in which the level of SCL transcripts was compared to(Figure 1). Three independent SCL 2/2 clones were
that of ubiquitously expressed hypoxanthine phosphori-isolated and compared in our experiments to three con-
bosyl transferase in RNAs obtained from ES cells, daytrol clones that remained heterozygous through selec-
7 EBs, and hematopoietic colonies of all types (Figuretion in G418.
3). Endogenous SCL expression was undetectable in
1/2 ES cells but evident in day 7 EBs and at a 2-foldSCL Expression Is Required for In Vitro
lower level in differentiated cells. SCL transgene expres-Myeloerythroid Hematopoiesis
sion was detected in ES cells and increased throughoutThe effects of SCL loss were first studied with in vitro
hematopoietic differentiation assays that permit enu- differentiation to a level greater than in wild-type cells
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Figure 2. In Vitro Differentiation of SCL 1/2,
SCL 2/2, and SCL 2/2R ES Cells
(A) Day 14 SCL 1/2, SCL 2/2, and SCL 2/2R
EBs are shown at the top. Note the absence
of hematopoietic cells surrounding the SCL
2/2 EB. EBs werethen disaggregated atvari-
ous days of differentiation and replated in dif-
ferent combinations of growth factors (see
Experimental Procedures). EryD, mixed ery-
throid/myeloid, macrophage (Mac.), and
megakaryocyte (Meg.) colonies derived from
SCL 1/2 and SCL 2/2R EBs are shown be-
low. No colonies were observed from SCL
2/2 EBs.
(B) The numbers of EryP,EryD, mixed,macro-
phage, megakaryocyte colonies derived from
SCL 1/2 and SCL 2/2R cells were scored
after replating of day 7 or day 10 EB cells in
various growth factors, as indicated (mean of
triplicate cultures). Combination: see Experi-
mental Procedures. Note the absence of any
colonies from SCL 2/2 ES cells.
(Figure 3). Significantly, introduction of expressible SCL SCL Is Required for In Vivo Development
of Hematopoietic LineagescDNA into SCL 2/2 ES cells restored myeloerythroid
development (see Figure 2). This finding provides defini- As SCL 2/2 embryos die at the yolk sac stage (Shivda-
sani et al., 1995), the requirement for SCL in definitivetive evidence that the block to myeloerythroid hemato-
poiesis in SCL 2/2 ES cells is solely due to loss of SCL. hematopoiesis in vivo was assessed in chimeras gener-
Figure 3. SCL RNA Expression in SCL 1/2
and SCL 2/2R Cells
RT–PCR analyses were performed with RNAs
obtained from undifferentiated ES cells, day
7 EBs, and hematopoietic colonies harvested
after differentiation of EB cells in a combina-
tion of growth factors. See Experimental Pro-
cedures for details.
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Table 1. Summary of Chimeras
Blastocysts ES cells RBC Mac. Meg. Mast Ly Other tissues
1/2 1 3/24 pools 2/16 pools 1 1 1
1 5/28 1/11 1 1 1
1 1/16 0/6 2 1 1
Wild-type 2/2 Clone 1 2 ↑ ↑ 2 2 1
2 2 2 1
2 2 2 1
2 0/12 to 24 0/8 to 16 2 2 1
2 pools pools 2 2 1
2/2Clone 2 2 2 2 1
2 2 2 1
2 2 2 1
2/2Clone 3 2 ↓ ↓ 2 2 1
2/2R 1 0/16 pools 0/7 pools 2 2 1
1 0/15 0/15 1 1 1
1 0/28 ND 2 1 1
RAG-2 2/2 2/2 Clone 1 ND 0/19 pools 0/12 pools 2 2 1
ND ND ND 2 2 1
2/2R ND ND ND 1 1 1
Contribution of ES–derived cells to hematopoietic lineages and nonhematopoietic tissues in SCL 1/2, SCL 2/2, and SCL 2/2R / wild-type
chimeras and SCL 2/2 and SCL 2/2R / RAG-2 deficient chimeras. RBC, red blood cells; mac, macrophages; meg, megakaryocytes; mast,
mast cells; ly, lymphocytes. ND, not determined.
ated by injection of ES cells into wild-type host blasto- blood (Figure 5A). Host blastocysts of the host C57Bl/6
strain are homozygous for the Hbbs haplotype, whereascysts. Chimeras were created with SCL 2/2 ES cell
clones, the rescued pool (SCL 2/2R), and SCL 1/2 strain 129/Sv ES cells are homozygous for the Hbbd
haplotype (Pevnyet al., 1991; Whitney, 1978). The contri-cells. Levels of coat color chimerism were estimated to
be 25%–60%. Chimeras were studied at the adult stage bution of ES–derived cells to red cells of chimeras was
evidenced by the presence of Hbbd (bracketed in Figure(4–5 weeks old).Data on the chimeras are summarized in
Table 1. Representative results from individual chimeras 5A). Chimeras made with SCL 1/2 and SCL 2/2R ES
cells displayed ES cell contribution, while those gener-are described below.
Overall contribution of donor ES–derived cells to chi- ated with SCL 2/2 ES cells did not. Hence, SCL expres-
sion is necessary for production of mature red bloodmeras was determined by Southern analysis of selected
tissues (Figure 4). While SCL 1/2 cells contributed to cells in adult animals.
Myeloid Cells, Megakaryocytes,all tissues tested (data not shown), SCL 2/2 cells con-
tributed to a variable extent to all nonhematopoietic and Mast Cells
Precursors in the bone marrow of chimeras were exam-tissues butconsistently did not contribute to hematopoi-
etic tissues, such as spleen and bone marrow. In con- ined using a hematopoietic colony assay. Upon culture
in methylcellulose media supplemented with appro-trast, SCL 2/2R cells contributed to both hematopoietic
and nonhematopoietic tissues. Specific assays were priate growth factors, bone marrow cells gave rise to
differentiated colonies, thereby reflecting hematopoieticemployed to examine the contribution of ES cells to
individual hematopoietic lineages. precursors initially present. Macrophage and megakary-
ocyte colonies were obtained by growth in the presenceDefinitive Erythroid Cells
The contribution of ES–derived cells tomature redblood of G-CSF/GM-CSF/IL-3 and Tpo/KL, respectively. In ad-
dition, bone marrow cells were cultured in IL-3–cellswas assessedby hemoglobin analysis of peripheral
Figure 4. Contribution of ES–Derived Cells to
Various Tissues in Chimeras Made with SCL
2/2 and SCL 2/2R ES Cells
Genomic DNAs were digested with BamHI
and subjected to Southern blot analysis as
described (Shivdasani et al., 1995). Note the
absence of SCL 2/2 ES cell contribution to
spleen and contribution by SCL 2/2R ES
cells. wt, wild-type allele; m, mutant allele.
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not show rescue of the macrophage or megakaryocyte
lineages analyzed as pools of a few individual colonies
(data not shown) but did show rescue in mast cells,
analyzed as an entire cell population (Figure 5B). From
these data and those summarized in Table 1, we con-
clude that SCL is required for macrophage, megakaryo-
cytic, and mast cell development.
B and T Lymphoid Cells
The contribution of ES–derived cells to lymphoid cells
was examined by fluorescence-activated cell sorter
(FACS) analyses. Triple staining of mononuclear cells
isolated from thymus, lymph nodes, spleen, and bone
marrow was performed using antibodies directed
against T or B cell–specific antigens (CD4, CD8, Thy1.2,
B220, IgM) and the allotypic marker Ly9.1 specifically
expressed on donor-derived lymphocytes. No contribu-
tion of SCL 2/2 ES–derived cells to the lymphoid com-
partment was observed, whereas SCL 1/2 cells gave
rise to both mature T and B lymphoid cells (Figure 6A).
Rescue of lymphopoiesis in SCL 2/2R cells was ob-
served (Figure 6B). ES–derived T and B cells were pres-
ent in the spleen of both SCL 1/2 and SCL 2/2R chime-
ras. The rescue appeared to be of low level, reflecting
the degree of chimerism and competition of SCL
2/2R–derived lymphoid precursors with host cells at
all stages of lymphopoiesis. These findings provided
initial, but perhaps not unequivocal, evidence that SCL
might be required for the development of lymphoid cells.
SCL Is Essential for Both B and T Cell
Lymphopoiesis In Vivo
To test more stringently a requirement for SCL in lym-
phopoiesis, we employed the RAG-2–deficient blasto-
cyst complementation assay (Chen et al., 1993). RAG-
22/2 cells, deficient for recombination-activating
Figure 5. Contribution of ES–Derived Cells to Hematopoietic Lin- gene-2 function, do not produce any mature B and T
eages of Chimeras Made with SCL 1/2, SCL 2/2, and SCL 2/2R
cells (Mombaerts et al., 1992; Shinkai et al., 1992). Chi-ES Cells
meras made with RAG-22/2 blastocysts as hosts pro-
(A) Hemoglobin analysis of red blood cells. Hbbs (H) is specific for
vide a highly sensitive assay system for detectinghostblastocyst cells and Hbbd (ES) is specific for ES cells. C, control.
lymphoid developmental potential of ES cells. Chimeras(B) Origin of macrophages, megakaryocytes, and mast cells in the
chimeras. DNA isolated from 14 pools of macrophage colonies (simi- were generated with either SCL 2/2 or SCL 2/2R ES
lar results were obtained from megakaryocyte colonies) or from cells (Chen et al., 1993). Chimerism and contribution of
mast cell cultures was amplified using allele-specific primers. m, ES cells to nonhematopoietic tissues were assessed by
mutated allele. wt, wild-type allele. C, control. Dots indicate three
Southern analysis (data not shown). Thymocytes, lymphpools of colonies containing cells derived from SCL 1/2 ES cells.
node cells, and splenocytes purified from chimeras, as
well as from RAG-22/2 and wild-type mice, were sub-
jected to FACS analyses (Figure 6C). The thymus, lymphcontaining liquid medium for 4 weeks to obtain pure
populations of mast cells. Pools of four macrophage or nodes, and spleen of RAG-22/2 mice contained very
few cells owing to the absence of CD4181 (double posi-megakaryocyte colonies aspirated from methylcellu-
lose, or cells from mast cell cultures, were lysed for PCR tive) and CD4182 or CD4281 (single positive) T cells and
B cells. SCL 2/2 ES–derived cells failed to give rise togenomic DNA analysis. PCR primer pairs designed for
selective amplification of the wild-type allele or the mu- double-positive cells in thymus, single-positive cells in
lymph nodes, or B220/IgM–positive B cells in spleen.tant allele (present in the three types of ES cell–derived
cells: SCL 1/2, SCL 2/2, and SCL 2/2R) were em- In contrast, SCL 2/2R chimeras displayed normal cell
numbers and appearance of lymphoid tissues. More-ployed. While the mutant allele was identified in macro-
phages and megakaryocytes derived from the SCL 1/2 over, FACS profiles were comparable to the profiles
obtained with wild-type mice, confirming reconstitutionchimeras, no mutant allele was observed from colonies
of chimeras made with SCL 2/2 ES cells (Figure 5B). of the lymphoid compartment.
To examine the function of lymphoid cells in chimerasMoreover, populations of cultured mast cells of chime-
ras made with SCL 2/2 ES cells did not reveal ES cell derived from SCL 2/2 and SCL 2/2R ES cells, lymph
node cells were isolated and exposed to anti-CD3e anti-contribution, whereas those made with heterozygous
cells did (Figure 5B). Analysis of SCL 2/2R chimeras did body, and proliferation was assayed. Lymph node cells
Cell
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Figure 6. Analysis of Lymphopoietic Potential of SCL 2/2 Cells
(A) ES–derived lymphoid cells fail to develop in chimeric mice generated with SCL 2/2 ES cells. Flow cytometric analysis of lymph node cells
from SCL 1/2 and SCL 2/2 ES cell–derived chimeric mice was performed using anti-Thy 1.2 and anti-B220 antibody conjugates as markers
of T and B cells, respectively. The anti-Ly 9.1 antibody was used to distinguish between ES cell–derived (Ly 9.11) and blastocyst-derived (Ly
9.12) lymphocytes, which express Ly 9.2 allele.
(B) Rescue of SCL 2/2 lymphocyte development by an SCL transgene. Spleen cells from SCL 1/2, SCL 2/2, or SCL 2/2R ES cell–derived
chimeric mice were analyzed for expression of Ly 9.1 marker by flow cytometry. A total of 5 3 104 (SCL 1/2) or 107 (SCL 2/2 or SCL 2/2R)
cells were acquired. The majority of Ly 9.1–negative cells was excluded from analysis by live gating. The Ly 9.1–positive lymphocytes in SCL
1/2, SCL 2/2R, or SCL 2/2 mice represented 10% of total, 0.05% of total, or were not detectable, respectively.
(C) Analysis of lymphopoietic potential of SCL 2/2 ES cells by the RAG-2–deficient blastocyst complementation assay. Fluorescence-staining
profiles of lymphoid cell populations from RAG-22/2 mice (C57BL6 3 129 strain), wild-type mice (129 strain), and chimeric mice derived by
injecting SCL 2/2 or SCL 2/2R ES cells into RAG-2–deficient blastocysts are shown, as well as total number of thymocytes and lymph node
cells. Thymocytes (THC), lymph node (LN), or spleen (SPL) cells were counted and analyzed by flow cytometry for expression of CD4 and
CD8 or B220 (CD45R) and IgM.
(D) Functional analysis of T cells from SCL 2/2R ES cell-derived chimera mice.
Total lymph node cells from wild-type (open squares) or RAG–deficient (closed squares) mice, or chimera mice derived from SCL 2/2R (open
diamonds), SCL 2/2 (open circles or open triangles) were stimulated by various concentrations of anti-CD3e antibodies in the presence of
exogenously supplied IL-2. Thymidine incorporation was measured at 64 hr. The results are displayed as mean cpm.
of SCL 2/2R chimeras proliferated indistinguishably myeloerythroid hematopoiesis but also for lymphopoie-
sis in vivo.from wild-type cells, whereas proliferation of the few
cellsobtained from RAG-22/2 or SCL2/2 lymph nodes
was undetectable (Figure 6D).
Summary of Chimera AnalysesThe inability of SCL 2/2 ES cells to contribute to
Results are summarized in Table 1. Of 11 SCL 2/2lymphopoiesis in the RAG-2–deficient complementation
chimeras isolated from three independent SCL 2/2 ESassay, taken together with the rescue of lymphoid devel-
opment upon reintroduction of SCL cDNA, provides cell clones (nine mice were generated with wild-type
blastocysts and two with RAG-22/2 blastocysts), noneconclusive evidence that SCL is essential not only for
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exhibited any contribution of ES–derived cells to hema- Surprisingly, constitutive SCL expression in SCL 2/2
ES cells in our experiments failed to inhibit myeloid dif-topoietic lineages. Contribution to nonhematopoietic
ferentiation in vitro (Figure 2). These divergent findingstissues was consistently observed. SCL 1/2 ES cells
most likely reflect differences between permanent cellcontributed to all tissues in chimeras. SCL 2/2R chime-
lines and totipotent ES cells or in levels of expressionras displayed rescue of hematopoiesis in all lineages
attained. Nonetheless, our results argue that lineage(except macrophages and megakaryocytes). Lympho-
selection or maturation does not require extinction ofpoiesis was strictly dependent on SCL, as described
SCL expression.above.
Though we readily demonstrated rescue of myeloid
and megakaryocytic development of SCL 2/2 ES cells
Discussion in vitro by constitutive expression of SCL cDNA, we did
not observe SCL 2/2R–derived colonies from chimeric
Prior studies have shown that SCL is necessary for pro- mice. We suspect that this reflects the relatively lower
duction of embryonic red blood cells (Shivdasani et al., chimerism of the hematopoietic compartment (com-
1995) and have also suggested a role in erythroid cell pared to coat color or other tissues) often seen with ES
maturation (Aplan et al., 1992; Green et al., 1991). The cells (Berger et al., 1995; our unpublished data) and the
experiments reported here reveal a broader requirement need to compete with host precursors in chimeras.
in hematopoiesis, one that very likely reflects involve-
ment of SCL in programming mesoderm to a blood cell An Unexpected Role in the Generation
fate or in formation or maintenance of immature hemato- of Lymphoid Cells
poietic progenitors or the hematopoietic stem cell. The requirement of SCL for development of the immune
These findings have important implications for the regu- system is unexpected, although limited expression has
latory networks operative in hematopoietic develop- been noted in the developing thymus (Kallianpur et al.,
ment and for leukemogenesis initiated by deregulated 1994; Mouthon et al., 1993). The hierarchy of hematopoi-
SCL. etic progenitors is variously depicted in the literature.
Often, myeloerythroid and lymphoid “stem cells” are
shown as distinct descendants of the hematopoieticEarly Requirement for SCL in
stem cell, although formal evidence for this model isHematopoietic Development
lacking. Whatever the true situation, the absence of lym-SCL 2/2 ES cells do not give rise to precursor or mature
phopoiesis from SCL 2/2 ES cells supports a require-hematopoietic cells of any lineage in vitro or in vivo.
ment for SCL at the earliest stages of hematopoieticTo validate our findings, we showed that constitutive
development.expression of SCL cDNA in SCL 2/2 ES cells provided
phenotypic rescue. Although SCL might in principle
Comparison to the Roles of Otherserve an important function or functions independently
Transcriptional Regulatorsduring the maturation of multiple lineages, it is more
Roles for other transcription factors in various aspects
likely that the phenotype we describe reflects an essen-
of hematopoiesis have been shown by gene targeting.
tial role in a cell or developmental pathway common to
Multilineage effects on hematopoiesis are seen for other
all lineages. Other observations support this view. First,
knockouts (such as GATA-2, PU.1, AML-1, ALL-1,
SCL is expressed within embryonic and extraembryonic c-myb, Ikaros), but none ablate production of all lin-
mesoderm by E7.5 of the developing mouse (Kallianpur eages and their precursors (Georgopoulos et al., 1994;
et al., 1994). Second, SCL is required for the develop- Mucenski et al., 1991; Okuda et al., 1996; Scott et al.,
ment of hematopoietic lineages, such as B and T lym- 1994; Tsai et al., 1994; Yu et al., 1995). In contrast, SCL
phocytes, in which expression in precursor populations loss affects production of all lineages. Hence, our data
or maturing cells is not detected (Visvader et al., 1991). are most compatible with the hypothesis that SCL
Third,we fail tosee abortive or developmentally arrested serves a nonredundant function early in hematopoietic
hematopoietic colonies upon in vitro differentiation of development but subsequent to ventral mesoderm for-
SCL 2/2 ES cells under conditions that permit identifi- mation (Figure 7).
cation of mutant precursors in other situations (Olson The potential roles for SCL at later stages of hemato-
et al., 1995; Weiss et al., 1994). Since no vestiges of poiesis within specific lineages, such as in erythroid,
hematopoietic precursors are detected, we conclude megakaryocytic, and mast cells (Aplan et al., 1992;
that hematopoiesis is blocked at an earlier step in the Green et al., 1991; Visvader et al., 1991), cannot be
absence of SCL. Finally, precedents exist for the role assigned from our findings. The profound consequence
of related bHLH factors in crucial developmental steps of SCL loss for hematopoiesis is surprising perhaps
in other tissues (Guillemot et al., 1993; Lee et al., 1995; given the overlapping expression pattern of a highly
Rudnicki et al., 1993). related bHLH family member, lyl-1 (Mellentin et al.,
Previous studies suggest that SCL expression may 1989). Of note, we find that enforced expression of lyl-1
interfere with, rather than favor, development of se- cDNA fails to rescue the development defect of SCL
lected hematopoietic cell types. For example, forced 2/2 cells (our unpublished data).
expression of SCL in monocytic M1 cells retards termi-
nal maturation and impairs growth factor respon- Multicomponent Transcriptional Complexes,
siveness (Tanigawa et al., 1993), while enforced expres- SCL, and Leukemia
sion in a bipotent line TF-1 interferes with monocytic, SCL forms heterodimers with ubiquitously expressed
E2A gene products and interacts with E-box motifs inbut not erythroid, differentiation (Hoang et al., 1996).
Cell
54
Figure 7. Proposed Step at Which SCL Is Es-
sential for Hematopoietic Development
SCL is necessary after formation of ventral
mesoderm, as no defect in vascular develop-
ment is evident in SCL 2/2 embryos (Shivda-
sani et al., 1995), but prior to the commitment
of early progenitors to the myeloerythroid and
lymphoid pathways. It is likely, therefore, to
participate in the specification of mesoderm
to an hematopoietic fate or in the develop-
ment of the earliest hematopoietic compart-
ment (or the hematopoietic stem cell itself).
and grown in 1.5 mg/ml G418 (Mortensen et al., 1992). Clones weretarget promoters (Hsu et al., 1991, 1994). SCL is also
isolated and analyzed by Southern blot analysis.present in a complex with Rbtn2 in erythroid and leuke-
mic T cells (Valge-Archer et al., 1994; Wadman et al.,
Retroviral Transfer of SCL cDNA to SCL 2/2 ES Cells1994; Larson et al., 1996). Of particular interest, misex-
Murine SCL cDNA (Begley et al., 1991) was subcloned into a murinepression of SCL or Rbtn2, as a result of chromosomal
stem cell viral vector harboring a puromycin-N-acetyltransferase
translocation or interstitial deletion, is associated with gene (MSCVpac; Hawley et al., 1994). The cDNA was cloned as a
leukemia. Moreover, SCL is also expressed in leukemic 1 kb Pfu-polymerase–generated PCR fragment between BglII and
EcoRI sites of the MSCVpac vector (primers for PCR: GAAGATCTATT cells that do not contain detectable rearrangements
GACGGAGCGGCCGCCGAGCGAG and GGCGAATTCTCACCGGGat the SCL locus (Bash et al., 1995). These observations
GGCCAGCCCCATCAGC). Transfection of the packaging cell linesuggest that SCL and Rbtn2 function in a multicompo-
and infection of the SCL 2/2 ES cells were performed as describednent transcriptional complex within a common pathway
(Pear et al., 1996). Briefly, BOSC23 cells were transiently transfected
in leukemic transformation and, perhaps, normally by the CaCl2 precipitate method in presence of 25 mM chloroquine.
within erythroid cells. The absence of embryonic red Retroviral supernatant was harvested 48 hr later and used to infect
ES cells. After 48 hr, cells were selected with 1 mg/ml puromycin.blood cell formation in both SCL 2/2 and Rbtn22/2
Small pools (12) of 5–10 resistant clones each were isolated, ex-yolk sacs (Robb et al., 1995a; Shivdasani et al., 1995;
panded, and tested for transgene expression by RT–PCR. The poolWarren et al.,1994) is consistent with a common function
used in our experiments was named SCL 2/2R.
for these proteins. Physical interaction of Rbtn2 and the
hematopoietic transcription factor GATA-1 (Osada et al.,
In Vitro ES Cell Hematopoietic Differentiation1995), taken together with transcriptional regulation of
In vitro hematopoietic differentiation was performed as described
the SCL gene by GATA factors (Aplan et al., 1990, 1992; (Keller et al., 1993). ES cell clones (SCL 1/2, SCL 2/2, or SCL
Lecointe et al., 1994), suggests that a complex regula- 2/2R) were permitted to form EBs. At various times, EBs were
disaggregated and replated into methylcellulose media containingtory circuitry involving SCL, Rbtn2 and GATA-1 (or the
combinations of growth factors. EryP and EryD precursors wererelated factor GATA-2) may function in prehematopoi-
enumerated by replating cells into medium containing Epo (2 U/ml)etic mesoderm or an early hematopoietic compartment.
and Epo/KL (50 ng/ml), respectively. Medium containing Epo/KL/
Although investigators previously failed to produce G-CSF (granulocyte colony–stimulating factor, 1 ng/ml)/GM-CSF
leukemias in transgenic mice with T cell–directed SCL (granulocyte–macrophage CSF, 5 ng/ml)/ IL-1 (103 U/ml)/IL-3 (10 ng/
expression (Robb et al., 1995b), M. Kelliher et al. (per- ml)/IL-6 (2 ng/ml)/IL-11 (5 ng/ml) supported the development of
mixed erythroid–myeloid colonies, G-CSF/GM-CSF/IL-3/IL-11 thesonal communication) have recently demonstrated the
differentiation of macrophage colonies, and thrombopoietin (Tpo,leukemogenic potential of misexpressed SCL. It is not
1.1 mg/ml) the development of megakaryocyte colonies. Epo, KL,possible at present to discriminate between two mecha-
and Tpo were provided by Amgen. All other growth factors were
nisms for leukemogenesis. On the one hand, aberrant purchased from RandD Systems.
SCL expression might sequester other bHLH proteins,
such as E2A gene products, and act in a dominant- Semiquantitative RT–PCR
negative fashion. Alternatively, heterodimers containing SCL expression was quantitated by RT–PCR performed on RNA
SCL might activate normally silent genes, thereby lead- isolated from SCL 2/2R ES cells,day 7 SCL 2/2R EBs, and hemato-
poietic colonies harvested after differentiation of EBs in a combina-ing to a commitment or proliferative program character-
tion of growth factors. In parallel, endogenous SCL expression wasistic of immature progenitors. If this were the case, a
quantitated from SCL 1/2 cells. RNAs were isolated by acid–phenolsubset of critical target genes acted upon by SCL in
extraction (Chomczynski and Sacchi, 1987) and RT–PCR performed
immature hematopoietic progenitors (or prehematopoi- as described (Weiss et al., 1994). cDNA was synthesized from 2 mg
etic mesoderm) and in leukemic cells might be in of RNA by Moloney murine leukemia virus reverse transcriptase
common. (Gibco/BRL) with oligo(dT) as primer, according to instructions of
the manufacturer. A fraction (one-tenth) of the synthesized cDNA
was used for PCR. PCR reactions were performed using Taq poly-Experimental Procedures
merase (Boehringer Mannheim) in 10% dimethyl sulfoxide according
to instructions of the manufacturer. Each reaction contained 0.1 mCiSelection of SCL 2/2 ES Cells
{a-32P}dCTP. Two sets of primers were added: one designed toHeterozygous SCL 1/2 ES cells (Shivdasani et al., 1995) were pas-
saged on gelatin-treated plates as described (Weiss et al., 1994) amplify 570 bp of the SCL sequence, CGCGGATCCACGGAGCGGC
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CGCCGAGCGCG and CCGGAATTCCGCGCCGCACTACTTTGGT b-mercaptoethanol, and various concentrations of plate-bond anti-
CD3e antibody (clone 145–2C11, Pharmingen). To optimize cultureGTG, and one designed to amplify 249 bp of the constitutively ex-
pressed hypoxanthine phosphoribosyl transferase transcripts (see conditions for T cell proliferation, exogenous IL-2 (5 ng/ml) was
supplied as a protein partially purified from concanavalin A–stim-Weiss et al., 1994). Reaction conditions were 958C for 50 s, 578C
for 60 s, and 728C for 60 s. Aliquots were removed after cycles 14, ulated rat splenocyte cultures. Cells were pulsed with 1 mCi 3H-
thymidine per well at 48 hr for an additional 16 hr and then harvested16, 18, and 20 and loaded onto a 4% polyacrylamide gel. After
electrophoresis, relative quantitations (SCL versus hypoxanthine and scintillation-counted. The data are displayedas raw cpm values.
All assays were conducted in duplicates.phosphoribosyl transferase) were performed using a Phosphorim-
ager (Molecular Dynamics). Control experiments without reverse
transcriptase in the cDNA synthesis reactions did not show specific Acknowledgments
PCR products (data not shown).
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